US drug firms Abbott and Enanta have moved their jointly developed hepatitis C (HCV) drugs to Phase II clinical trials.
The trial will evaluate three HCV antiviral agents, ABT-450, ABT-333 and ABT-072.
Go deeper with GlobalData
ABT-450, an investigational protease inhibitor, is part of the Abbott-Enanta collaboration while the polymerase inhibitors ABT-333 and ABT-072 are being developed by Abbott.
The Phase II trials are aimed at assessing the antiviral activity, pharmacokinetics, safety and tolerability of multiple dose strengths of ABT-450, ABT-333 and ABT-072, dosed individually in treatment-naïve adults infected with HCV genotype 1.
Initial antiviral activity will be evaluated over a three-day monotherapy period and subsequently each antiviral agent will be administered with pegIFN/RBV for 12 weeks, followed by treatment with standard of care alone for an additional 36 weeks.
The trial participants will then be monitored for sustained virologic response.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataHepatitis C affects 170 million people worldwide.
